Brege Laura sold 10,907 shares of Mirum Pharmaceuticals, Inc. at $94.05 for −$1.03M on Nov 11, 2026

Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Director
DIR
Filed Nov 13, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$1,025,803.35Shares × reported price
Shares traded
10,907Common Stock
Price per share
$94.05Reported price. Read footnotes for ranges.
% of reported position traded
36.51%This security and ownership context
Holdings after
18,963Direct
Trade date
Nov 11, 2026Sell
Filed
Nov 13, 2026, 4:54 PM ET2-day reporting delay
Accession
0001365619-26-000007Code S · Transaction 400979
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 29,870 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Nov 11, 2026Option exercise14,167$0.00$0Trade 400981
Nov 11, 2026Sell3,260$94.74−$308,852.40Trade 400980
Nov 11, 2026Option exercise14,167$16.71$236,730.57Trade 400978
4 transaction rows in this filing. Joint filers share the same rows.

MIRM price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
MIRM · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 20, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago −8.4%1w ago +3.2%1d ago +0.5%
Returns since7d30d90d180d1y

Footnotes in full

F1: The weighted average sale price for the transaction reported was $94.05, and the range of prices were between $93.63 and $94.61. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. F2: The weighted average sale price for the transaction reported was $94.74, and the range of prices were between $94.635 and $94.91. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. F3: The stock option is fully vested.